Category
Biologics & Advanced Therapies
Modern targeted treatments for moderate-severe IBD
Simponi vs Omvoh for Ulcerative Colitis: Which Is Better?
Simponi and Omvoh represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2, making it the first IL-23 p19-selective biologic approved for UC. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and distinctive urgency data. This guide walks through the simponi vs omvoh ulcerative colitis comparison.
Simponi vs Humira for Ulcerative Colitis: Comparing Anti-TNFs
Simponi and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe ulcerative colitis. Both block TNF-alpha through fully human IgG monoclonal antibody structures, so their mechanisms are closely related. The main practical differences come down to dosing frequency (monthly for Simponi vs every other week for Humira), biosimilar availability, and trial data. This guide walks through the simponi vs humira ulcerative colitis comparison.
Simponi vs Entyvio for Ulcerative Colitis: A Comparison
Simponi and Entyvio take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic that targets alpha-4-beta-7 integrin. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with favorable systemic safety. This guide walks through the simponi vs entyvio ulcerative colitis comparison.
Omvoh vs Stelara for Ulcerative Colitis: Patient Guide
Omvoh and Stelara both target IL-23 pathway inflammation in moderate-to-severe ulcerative colitis, but with different mechanism specificity and clinical profiles. Stelara is an IL-12/23 p40 biologic approved for UC in October 2019 based on UNIFI. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on LUCENT-1 and LUCENT-2. Patients choosing between these two non-anti-TNF IL-23 pathway drugs often weigh mechanism specificity, urgency outcomes, and long-term dosing. This guide walks through the omvoh vs stelara ulcerative colitis decision.
Omvoh vs Stelara for Crohn's Disease: Key Differences
Omvoh and Stelara are two IL-23 pathway biologics for moderate-to-severe Crohn's disease, but they target the pathway at different points. Stelara blocks both IL-12 and IL-23 through the shared p40 subunit. Omvoh selectively blocks only IL-23 through its p19 subunit. The scientific rationale behind p19 selectivity is that IL-23 is the dominant driver of Crohn's inflammation while IL-12 plays broader immune roles that may not need blocking. Omvoh's VIVID-1 trial directly compared mirikizumab with ustekinumab as an active comparator, giving patients meaningful head-to-head data. This guide walks through the omvoh vs stelara crohn's decision.
Omvoh vs Remicade for Ulcerative Colitis: Patient Guide
Omvoh and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Omvoh is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade ulcerative colitis decision.
Omvoh vs Remicade for Crohn's Disease: Which to Choose?
Omvoh and Remicade represent two very different generations of Crohn's biologic therapy. Remicade has been the anti-TNF standard for Crohn's since the late 1990s. Omvoh is the newest IL-23 p19-selective biologic for Crohn's, gaining FDA approval in January 2025 based on the VIVID-1 trial. Patients commonly compare these drugs when choosing a first-line biologic or when weighing alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade crohn's comparison.
Omvoh vs Humira for Ulcerative Colitis: Which Is Right?
Omvoh and Humira take different mechanistic approaches to moderate-to-severe ulcerative colitis. Humira is the established anti-TNF with more than a decade of UC experience. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials, making it the first drug in its class approved for UC. Patients choosing between these drugs weigh mechanism, safety, and long-term administration convenience. This guide walks through the omvoh vs humira ulcerative colitis decision.
Omvoh vs Humira for Crohn's Disease: A Comparison
Omvoh and Humira are two biologics for moderate-to-severe Crohn's disease that work through very different mechanisms. Humira is a fully human anti-TNF biologic with more than two decades of experience in IBD. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on the VIVID-1 trial. Patients weighing these two drugs are often choosing between an established anti-TNF and a newer IL-23 option. This guide walks through the omvoh vs humira crohn's decision.
Omvoh vs Entyvio for Ulcerative Colitis: A Comparison
Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the omvoh vs entyvio ulcerative colitis comparison.
Omvoh vs Entyvio for Crohn's Disease: A Comparison
Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on VIVID-1. Entyvio is gut-selective and has been a Crohn's treatment option since 2014. Patients comparing these drugs often prioritize long-term safety or are weighing alternatives after anti-TNF failure. This guide walks through the omvoh vs entyvio crohn's decision.
Humira vs Remicade for Ulcerative Colitis: Patient Guide
Humira and Remicade are the two most widely prescribed anti-tumor necrosis factor (anti-TNF) biologics for ulcerative colitis. Both have treated moderate-to-severe UC for more than fifteen years, both are now available as lower-cost biosimilars, and both can help patients reach steroid-free remission. The choice between them usually comes down to how you want to receive your medication, how your insurance handles biosimilars, and which practical trade-offs fit your life. This guide walks through what UC patients typically weigh when deciding between humira vs remicade ulcerative colitis therapy.